Safety and Performance of the Affera SpherePVI™ Multi-Ablation System to Treat Paroxysmal Atrial Fibrillation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMedtronic Cardiac Ablation Solutions

About this trial

A prospective, single-arm, multi-center study to evaluate the safety, performance, and effectiveness of the Affera SpherePVI™ Multi-Ablation System for treating paroxysmal atrial fibrillation.

Eligibility criteria

Qualifiers

A physician's note indicating recurrent AF

At least two electrocardiographically documented AF episodes within 12 months prior to enrollment

Failure or intolerance of at least one Class I-IV anti-arrhythmic drug.

Suitable candidate for catheter ablation.

Disqualifiers

Continuous AF lasting more than 12 months (long-standing persistent AF).

AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, or reversible or non-cardiac cause.

Previous left atrial catheter or surgical ablation (including septal closure or left atrial appendage closure).

Valvular cardiac surgical/percutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).

Trial design

Treatments tested in this trial

  • SpherePVI™ Catheter

Treatment groups

150 Participants
are divided into 1 treatment group